What You Should Know:
– Luminopia, a digital health company focused on treating neuro-visual disorders, announced today that Highmark has approved coverage for its FDA-cleared therapy for children with amblyopia.
– This decision marks a significant milestone for Luminopia, as it expands access to its innovative treatment for a condition that affects millions of children.
What is Amblyopia?
Amblyopia, commonly known as lazy eye, is a leading cause of vision loss in children. Traditional treatments, such as eye patches and atropine drops, often result in poor patient compliance and limited efficacy. Luminopia offers a unique alternative by engaging children in therapeutic video content while addressing the underlying cause of amblyopia.
Highmark Health for Treatment of Pediatric Amblyopia
Highmark’s decision to cover Luminopia’s therapy underscores the company’s commitment to providing access to innovative treatments for its members. By approving this coverage, Highmark recognizes the unmet need for effective amblyopia therapies and the potential benefits of Luminopia’s technology.
Luminopia’s therapy has demonstrated significant improvements in vision within 12 weeks of treatment, with minimal daily usage. The company’s focus on patient engagement and compliance has led to positive outcomes for children with amblyopia.
“We appreciate Highmark’s thoughtful and rigorous approach to assessing new technologies, which can serve as a model for other health plans interested in bringing innovative therapies to their members. Meeting the Highmark NTAC’s high standards for clinical evidence is a significant validation of our technology and the impact it can have on patients with amblyopia,” said Scott Xiao, co-founder and CEO of Luminopia. “We are committed to making our treatment as accessible as possible for patients in need, and this approval brings us closer to our mission of transforming the standard of care for amblyopia.”
